For such heavily pre-treated HER2-positive breast cancer patients, chemotherapy with a trastuzumab biosimilar, Herzuma® may still be a viable option, as it has shown similar efficacies and safety profiles to previous studies. Here, ERBB2 is linked to breast cancer.